

Pilot study to investigate the endocrinological, physiological and pain-reducing effects of gamma-hydroxybutyric acid in combination with operant behaviour pain therapy on patients with FibroMyalgia Syndrome

Submission date 16/10/2007	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 06/02/2008	Overall study status Completed	☐ Statistical analysis plan
		☒ Results
Last Edited 19/05/2022	Condition category Musculoskeletal Diseases	☐ Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Dr. Claudia Spies

Contact details
Charite - Universitätsmedizin Berlin
Chariteplatz 1
Berlin
Germany
D-10117
+49 (0)30 450 531 012/52
claudia.spies@charite.de

Additional identifiers

Clinical Trials Information System (CTIS)
2005-002475-32

Protocol serial number

Study information

Scientific Title

Pilot study to investigate the endocrinological, physiological and pain-reducing effects of gamma-hydroxybutyric acid in combination with operant behaviour pain therapy on patients with FibroMyalgia Syndrome

Acronym

FMS

Study objectives

Title in German: Pilotstudie zu den endokrinologischen, peripherphysiologischen und schmerzreduzierenden Effekten von Gamm-Hydroxybuttersäure in Kombination mit operant-verhaltenstherapeutischer Schmerztherapie bei Patienten mit Fibromyalgiesyndrom

In our study we will test the following hypotheses:

1. After the multimodal therapy composed of gamma-hydroxybutyric acid (GHB) and behavioural therapy (operant pain therapy) in the experimental group in comparison with the control group, we expect a decrease of pain-induced damage, the rate of consultations in the last 12 months and the multidimensional pain inventory (MPI) (primary target goals)
2. The intake of GHB in the experimental group increases growth hormone and cortisol and decreases adrenocorticotrophic hormone (ACTH). We expect an increase of muscular tension, a decrease of blood pressure, heart rate and resistance of the skin. A potential effect of GHB increases life control and reduces depressive mood (secondary target goals)

On 03/07/2008 the sources of funding field was updated. The previous text was: 'German Research Council (Deutsche Forschungsgemeinschaft [DFG]) (Germany) - grant application pending'

On 14/01/2009 the anticipated end date was changed from 01/12/2008 to 01/12/2009.

On 04/02/2010 the anticipated end date was changed from 01/12/2009 to 31/12/2010.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics board committee Berlin, Landesamt für Gesundheit und Soziales (LaGeSo), 30/11/2005, ref: EA1/160/05

Study design

Placebo-controlled double-blind randomised pilot study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Fibromyalgia

Interventions

GHB oral

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Gamma-hydroxybutyric acid (GHB)

Primary outcome(s)

1. Number of physician consultations in the last 12 months
2. Multidimensional Pain Inventory (MPI)

Outcomes measured at:

1. Pre-examination: start of the intake of study drug
2. Two months after starting the intake of study drug
3. Post-examination: end of the intake of study drug
4. Catamnesis 1: 2 months after the intake of study drug
5. Catamnesis 2: 6 months after the intake of PP

Key secondary outcome(s)

1. Muscular tension
2. Blood pressure
3. Heart rate
4. Resistance of the skin
5. Assessment of life control and depressive mood

Outcomes measured at:

1. Pre-examination: start of the intake of study drug
2. Two months after starting the intake of study drug
3. Post-examination: end of the intake of study drug
4. Catamnesis 1: 2 months after the intake of study drug
5. Catamnesis 2: 6 months after the intake of PP

Completion date

31/12/2010

Eligibility**Key inclusion criteria**

1. Verified fibromyalgia
2. Female sex
3. Sound command of German language
4. Motivation for therapy

5. Minimum age 18 years
6. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Female

Key exclusion criteria

1. Patients under 18 years or older than 80 years
2. Pregnancy
3. Psychiatric disease
4. Treatment with opioids
5. Treatment with sedative drugs
6. Current intake of anti-depressants
7. Pension demand
8. Patients without the possibility to give their consent
9. Arterial hypertension
10. Epilepsy
11. Severe renal failure
12. Intoxication with alcohol
13. Inclusion in another study within the last 30 days

Date of first enrolment

01/10/2006

Date of final enrolment

31/12/2010

Locations**Countries of recruitment**

Germany

Study participating centre

Charite - Universitätsmedizin Berlin

Berlin

Germany

D-10117

Sponsor information

Organisation

Charite - University Medicine Berlin (Charite - Universitätsmedizin Berlin) (Germany)

ROR

<https://ror.org/001w7jn25>

Funder(s)

Funder type

Government

Funder Name

Charite - University Medicine Berlin (Charite - Universitätsmedizin Berlin) (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

Not provided at time of registration

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results		09/09/2020	19/05/2022	No	No